Clinical Trial Update: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of palbociclib and INCMGA00012 in advanced well-differentiated or dedifferentiated liposarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Well-differentiated Liposarcoma

Drugs mentioned

• INCMGA00012
• Palbociclib (palbociclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Well-differentiated/Dedifferentiated Liposarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING